Eric Roselli, M. D.

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Eric Roselli, M. D. sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Eric Roselli, M. D.: 1 sponsored US clinical trial, 1 recruiting.

Eric Roselli, M. D. sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Congenital Aortic Anomaly, with 1 trials.

Mid-pack sponsor footprint

Eric Roselli, M. D. is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair

NCT04747626

Therapeutic Areas

Congenital Aortic Anomaly 1
Aortic Dissection 1
Thoracic Aortic Aneurysm 1

What is open in the Eric Roselli, M. D. pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Congenital Aortic Anomaly (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Eric Roselli, M. D.: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Eric Roselli, M. D. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Eric Roselli, M. D.1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Eric Roselli, M. D. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Eric Roselli, M. D. sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Eric Roselli, M. D. page

1 registered trials is a research-attention snapshot, not an endorsement of Eric Roselli, M. D. or any single study.

  • 1 of Eric Roselli, M. D.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Congenital Aortic Anomaly is the condition Eric Roselli, M. D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Congenital Aortic Anomaly trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Eric Roselli, M. D. pipeline card: 1 registered trials from official public datasets.Report a data error.